Page last updated: 2024-12-06

flupirtine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Flupirtine is a centrally acting analgesic drug that was originally marketed as a treatment for chronic pain. It acts by blocking the release of excitatory neurotransmitters, including glutamate and substance P, in the spinal cord and brain. Flupirtine is thought to exert its analgesic effects through modulation of the NMDA receptor and by activating the glycine receptor. However, it is not fully understood how flupirtine works. Flupirtine is a complex molecule that was initially synthesized in the 1970s. The synthesis involves multiple steps and requires specialized expertise. Although flupirtine was initially hailed as a promising new analgesic, its use has been significantly limited due to concerns about hepatotoxicity. Studies have shown that flupirtine can cause liver damage, particularly in individuals who are predisposed to liver disease. As a result, flupirtine is no longer widely available in many countries. Despite its controversial history, research on flupirtine continues. Some studies suggest that it may have therapeutic potential in treating conditions such as neuropathic pain, fibromyalgia, and multiple sclerosis. However, further research is needed to clarify the safety and efficacy of flupirtine in these conditions. Flupirtine is studied because it has unique properties that make it a potential treatment for chronic pain and other conditions. However, its use is limited due to safety concerns. More research is needed to determine the true potential of flupirtine.'

flupirtine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53276
CHEMBL ID255044
CHEBI ID94646
SCHEMBL ID25009
MeSH IDM0105473
PubMed CID6435335
CHEMBL ID1256752
SCHEMBL ID124707
MeSH IDM0105473

Synonyms (143)

Synonym
gtpl2598
lopac-f-8927
NCGC00015451-01 ,
LOPAC0_000547
c15h17fn4o2
ethyl 2-amino-6-((p-fluorobenzyl)amino)-3-pyridinecarbamate
flupirtine
flupirtino [inn-spanish]
flupirtinum [inn-latin]
carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester
flupirtine [inn:ban]
einecs 260-503-8
NCGC00162182-01
MLS002153180 ,
smr001230672
NCGC00015451-04
CHEMBL255044
w-2964 ,
flupirtinte
flupirtine (inn)
D07978
56995-20-1
ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate
CCG-204637
moh3et196h ,
unii-moh3et196h
flupirtino
flupirtinum
NCGC00015451-03
NCGC00015451-02
NCGC00015451-06
DB06623
CS-1746
HY-17001A
SCHEMBL25009
flupirtinte [vandf]
flupirtine [mi]
flupirtine [who-dd]
flupirtine [inn]
carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester, (z)-2-
flupirtine [vandf]
DTXSID4048436
2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine
carbamic acid, [2-amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-, ethyl ester
n-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester;(z)-2-butenedioate
bdbm81199
(z)-but-2-enedioate;ethyl n-[2-azanyl-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
n-[2-amino-6-[(4-fluorobenzyl)amino]-3-pyridyl]carbamic acid ethyl ester;maleate
(z)-but-2-enedioate;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
cid_25162978
AKOS024457318
ethyl {2-amino-6-[(4-fluorobenzyl)amino]pyridin-3-yl}carbamate
STL483409
CHEBI:94646
flupirtine, analytical standard
n-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester
flupirtine; n-[2-amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbamic acid ethyl ester; d 9998; katadolon; trancopal dolo
flupirtin
Q415403
ethyl (2-amino-6-((4-fluorobenzyl)amino)pyridin-3-yl)carbamate
1198579-27-9
SDCCGSBI-0050530.P002
NCGC00015451-17
AS-56215
AC-454
HY-17001
flupirtine (maleate)
katadolon
d-9998
flupirtine maleate ,
effirma
carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester, (z)-2-butenedioate (1:1)
ethyl-n-(2-amino-6-(4-fluorophenylmethylamino)pyridin-3-yl)carbamate maleate
ethyl 2-amino-6-((p-fluorobenzyl)amino)-3-pyridinecarbamate maleate (1:1)
einecs 278-225-0
flupirtin-maleat [german]
w 2964m
flupirtine maleate [usan]
(2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)carbamic acid ethyl ester maleate
ethyl 2-amino-6-((4-fluorobenzyl)amino)pyridine-3-carbamate, compound with maleic acid (1:1)
ethyl-n-(2-amino-6-(4-fluor-phenylmethylamino)pyridin-3-yl)carbamat maleat [german]
EU-0100547
flupirtine maleate salt, >=98% (hplc)
75507-68-5
D04226
flupirtine maleate (usan)
NCGC00093935-01
F 8927
2-amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-carbamic acid, ethyl ester maleate
133AP001
(z)-but-2-enedioic acid; ethyl n-[2-azanyl-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
n-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester; (z)-2-butenedioic acid
A838439
NCGC00093935-02
HMS3261N15
unii-0vci53pk4a
ethyl-n-(2-amino-6-(4-fluor-phenylmethylamino)pyridin-3-yl)carbamat maleat
0vci53pk4a ,
flupirtin-maleat
flupirtinte maleate
w-2964m
CHEMBL1256752
tox21_113397
2-amino-3-(ethoxycarbonylamino)-6-(4-fluorobenzylamino)pyridine maleate salt
F0736
flupirtine maleate salt
dtxsid8045771 ,
tox21_111232
dtxcid6025771
cas-75507-68-5
BCP9000699
[2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester maleate
ethyl (2-amino-6-((4-fluorobenzyl)amino)pyridin-3-yl)carbamate maleate
LP00547
CS-0573
flupirtine maleate [vandf]
flupirtine maleate [who-dd]
flupirtinte maleate [vandf]
flupirtine maleate [mart.]
flupirtine maleate [mi]
CCG-221851
SCHEMBL124707
DPYIXBFZUMCMJM-BTJKTKAUSA-N
NCGC00015451-05
tox21_111232_1
tox21_500547
NCGC00261232-01
AKOS024286722
diethyl4-fluorophenylmalonate
n-[2-amino-6-[[4-fluorophenyl)methyl]amino]-3-pyridinyl]carbamic acid ethyl ester maleate
Q-101869
mfcd00941415
SR-01000075887-1
sr-01000075887
katadolon maleate
flupirtinmaleat
75507-68-5 (maleate).
carbamic acid, [2-amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-, ethyl ester, (z)-2-butenedioate (1:1)
flupirtinemaleate
Q27231153
flupirtine maleate- bio-x
BF164473

Research Excerpts

Overview

Flupirtine (FLU) is a non-opioid analgesic with no antipyretic or anti-inflammatory effects which is used in the treatment of pain in humans. It is reported to act on neuronal ion channels and neurotransmitter receptors.

ExcerptReferenceRelevance
"Flupirtine is a non-opioid centrally acting analgesic that has been in clinical use, and is reported to act on neuronal ion channels and neurotransmitter receptors. "( Anti-nociceptive and anxiolytic effects of systemic flupirtine and its direct inhibitory actions on in vivo neuronal mechanical sensory responses in the adult rat anterior cingulate cortex.
Fujino, Y; Furue, H; Matsumoto, Y, 2020
)
2.25
"Flupirtine is a KCNQ potassium channel opener."( Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy.
Raol, YH; Sampath, D; Valdez, R; White, AM, 2017
)
1.48
"Flupirtine maleate is a centrally acting, non-opioid, nonsteroidal antiinflammatory analgesic. "( Isolation, identification and characterization of novel process-related impurities in flupirtine maleate.
Song, X; Su, J; Zhang, D, 2014
)
2.07
"Flupirtine (FLU) is a non-opioid analgesic drug with no antipyretic or antiphlogistic effects, used in the treatment of a wide range of pain states in human beings. "( Pharmacokinetic profiles of the analgesic drug flupirtine in cats.
De Vito, V; Giorgi, M; Kowalski, CJ; Lebkowska-Wieruszewska, B; Owen, H, 2014
)
2.1
"Flupirtine (FLU) is a non-opioid analgesic with no antipyretic or anti-inflammatory effects which is used in the treatment of pain in humans. "( Pharmacokinetic profiles of the analgesic flupirtine in dogs after the administration of four pharmaceutical formulations.
De Vito, V; Giorgi, M; Kowaski, CJ; Lisowski, A; Shaban, A; Łebkowska-Wieruszewska, B, 2015
)
2.12
"Flupirtine is a nonopioid, central analgesic without antipyretic or antiphlogistic properties. "( Effects of advanced age and renal dysfunction on the single- and repeated-dose pharmacokinetics of modified-release flupirtine.
de Mey, C; Deliyska, B; Gatchev, E; Terhaag, B, 2015
)
2.07
"Flupirtine is an indirect NMDAR antagonist being used as analgesic in patients."( The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis.
Bähr, M; Doeppner, TR; Hermann, DM; Jaeger, HM; Kaltwasser, B; Kilic, E; Pehlke, JR, 2015
)
1.43
"Flupirtine (FLU) is a non-opioid analgesic drug, with no antipyretic or anti-inflammatory effects, used in the treatment of a wide range of pain states in human beings. "( Pharmacokinetics and disposition of flupirtine in the horse.
De Vito, V; Giorgi, M; Owen, H; Poapolathep, A; Rychshanova, R; Sgorbini, M, 2016
)
2.15
"Flupirtine is a nonopioid analgesic with regulatory approval in a number of European countries. "( HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.
Aithal, GP; Bjornsson, ES; Cascorbi, I; Coulthard, SA; Daly, AK; Floratos, A; Gundert-Remy, U; Nelson, MR; Nicoletti, P; Sawle, A; Shen, Y; Stammschulte, T; Urban, TJ; Werk, AN, 2016
)
2.12
"Flupirtine is an established clinical analgesic for mild to moderate musculoskeletal pain states. "( Combination therapy with flupirtine and opioid: studies in rat pain models.
Cooke, I; Goodchild, CS; Kolosov, A; Tucker, AP, 2008
)
2.09
"Flupirtine is a nonopioid drug without antipyretic or antiphlogistic properties and with a favorable tolerability. "( Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Klawe, C; Maschke, M, 2009
)
3.24
"Flupirtine is an activator of Kv7 (KCNQ/M) potassium channels that has found clinical use as an analgesic with muscle relaxant properties. "( The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve.
Carr, RW; Grafe, P; Schwarz, JR; Sittl, R, 2010
)
2.08
"Flupirtine is an anti apoptotic agent which has been used with limited success in Alzheimer disease, prion diseases and neuronal ceroid lipofuscinosis which is a inherited disease of apoptosis related genes."( Flupirtine may stop the progressive course of subacute sclerosing panencephalitis.
Ekici, B; Ozmen, M; Tatli, B, 2010
)
2.52
"Flupirtine is a centrally acting, non-opioid analgesic that is available in a number of European countries for the treatment of a variety of pain states. "( Flupirtine in pain management: pharmacological properties and clinical use.
Devulder, J, 2010
)
3.25
"Flupirtine is a non-opioid analgesic drug acting via the enhancement of so-called M currents, associated to Kv7 potassium channels in the central nervous system."( Flupirtine antinociception in the rat orofacial formalin test: an analysis of combination therapies with morphine and tramadol.
Capuano, A; De Corato, A; Navarra, P; Treglia, M; Tringali, G, 2011
)
2.53
"Flupirtine is a widely known analgesic drug that is approved for the treatment of acute and chronic pain, particularly musculoskeletal pain. "( The evolving understanding of the analgesic mechanism of action of flupirtine.
Pergolizzi, JV; Raffa, RB, 2012
)
2.06
"Flupirtine is a non-opioid analgesic that has been in clinical use for more than 20 years. "( Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine.
Boehm, S; Chandaka, GK; Dorostkar, MM; Geier, P; Klinger, F; Kubista, H; Salzer, I; Yousuf, A, 2012
)
2.04
"Flupirtine is an analgesic with muscle-relaxing properties that activates Kv7 potassium channels. "( Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Averbeck, B; Carr, RW; Fleckenstein, J; Irnich, D; Lang, PM; Sittl, R, 2013
)
2.07
"Flupirtine is a triaminopyridine derived centrally acting analgetic, which has been found to display neuroprotective effects in models of excitotoxic cell damage, global, and focal ischemia, but no direct interaction with any component of the N-methyl-D-aspartate (NMDA) and glutamate triggered Ca(2+)-channel. "( Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation.
Armony, T; Finberg, JP; Gassen, M; Lamensdorf, I; Youdim, MB, 2003
)
2
"Flupirtine is a centrally acting nonopioid analgesic with muscle-relaxant properties. "( The potassium channel modulator flupirtine shifts the frequency-response function of hippocampal synapses to favour LTD in mice.
Azad, SC; Dodt, HU; Eder, M; Hapfelmeier, G; Rammes, G; Simon, W; Zieglgänsberger, W, 2004
)
2.05
"Flupirtine is a novel non-opiate centrally acting analgesic agent with muscle relaxant properties, advocated for use in a number of pain states. "( Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.
Fitton, A; Friedel, HA, 1993
)
3.17
"Flupirtine is a triaminopyridine analogue which has been successfully applied in clinics as a non-opiate analgesic drug. "( Flupirtine increases the levels of glutathione and Bc1-2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect.
Müller, WE; Pergande, G; Perovic, S; Pialoglou, P; Schröder, HC, 1996
)
3.18
"Flupirtine is a non-opioid, centrally acting analgesic which has been shown to be neuroprotective against N-methyl-D-aspartate (NMDA)-mediated toxicity in vitro."( Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats.
Block, F; Pergande, G; Schwarz, M, 1997
)
2.46
"1. Flupirtine (Katadolon) is a member of a class of triaminopyridines and is used as a nonopioid analgesic agent with muscle relaxant properties. "( Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist.
Block, F; Cazevieille, C; Kosinski, C; Nash, MS; Osborne, NN; Pergande, G; Schwarz, M; Wood, JP, 1998
)
2.36
"1. Flupirtine is an analgesic agent which exhibits neuronal cytoprotective activity and may have value in the treatment of conditions involving cell injury and apoptosis. "( Effect of the triaminopyridine flupirtine on calcium uptake, membrane potential and ATP synthesis in rat heart mitochondria.
Balakirev, M; Hofmann, M; Pergande, G; Woodcock, BG; Zimmer, G; Zwicker, K, 1998
)
1.21
"Flupirtine is a triaminopyridine-derived centrally acting analgesic, which interacts with mechanisms of noradrenergic pain modulation. "( Antioxidant properties of the triaminopyridine, flupirtine.
Gassen, M; Pergande, G; Youdim, MB, 1998
)
2
"Flupirtine is an analgesic drug thought to have NMDA receptor antagonistic and antiapoptotic effects. "( Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells.
Evert, BO; Klockgether, T; Kovar, KA; Rundfeldt, C; Schulz, JB; Seyfried, J; Wüllner, U, 2000
)
3.19
"Flupirtine is a new non-opioid, non-addicting centrally acting analgesic. "( Pharmacological profile of flupirtine, a novel centrally acting, non-opioid analgesic drug.
Nickel, B; Szelenyi, I, 1991
)
2.02
"1. Flupirtine is a novel and, in all probability, centrally acting, analgesic. "( Dose-related analgesic effects of flupirtine.
Borbe, HO; Friedmann, T; Hummel, T; Kobal, G; Niebch, G; Pauli, E, 1991
)
1.18
"1. Flupirtine is a novel, centrally acting, non-opioid analgesic agent. "( Mode of antinociceptive action of flupirtine in the rat.
Borbe, HO; Brune, K; Nickel, B; Szelenyi, I, 1989
)
1.18
"Flupirtine is a novel analgesic recently introduced with therapy. "( Flupirtine antinociception in the dog is primarily mediated by nonopioid supraspinal mechanisms.
Becketts, K; Nickel, B; Vaupel, DB, 1989
)
3.16
"Flupirtine maleate is a centrally acting analgesic with a novel chemical structure and pharmacological profile. "( Abuse potential and physical dependence liability studies with flupirtine maleate in laboratory animals.
Diamantis, W; Gordon, R; Sofia, RD, 1987
)
1.96

Effects

Flupirtine has a unique chemical structure and differs in its profile of effects and side effects from established NSAIDs (non-steroidal anti-inflammatory drugs) on the one hand and from opioids on the other.

Flupirtine has a unique chemical structure and differs in its profile of effects and side effects from established NSAIDs (non-steroidal anti-inflammatory drugs) on the one hand and from opioids on the other hand. It prevents the toxic effect of PrP, the presumed etiologic agent of Creutzfeldt-Jakob disease as well as the excitatory amino acid glutamate on cortical neurons.

ExcerptReferenceRelevance
"Flupirtine has a unique chemical structure and differs in its profile of effects and side effects from established NSAIDs (non-steroidal anti-inflammatory drugs) on the one hand and from opioids on the other hand."( [Long-term-treatment of chronic pain patients with flupirtine--on hepatotoxicity and persistent effectiveness from 7 months to 22 years].
Wörz, R, 2014
)
1.38
"Flupirtine has a different structure from existing analgesics. "( Flupirtine--a new centrally acting analgesic with unique chemical structure.
Engel, J, 1987
)
3.16
"Flupirtine has a unique chemical structure and differs in its profile of effects and side effects from established NSAIDs (non-steroidal anti-inflammatory drugs) on the one hand and from opioids on the other hand."( [Long-term-treatment of chronic pain patients with flupirtine--on hepatotoxicity and persistent effectiveness from 7 months to 22 years].
Wörz, R, 2014
)
1.38
"Flupirtine has been shown in vitro to reduce apoptosis in CLN3 lymphocytes."( Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data.
Adams, H; Augustine, EF; Cialone, J; de Blieck, EA; Kwon, J; Marshall, FJ; Mink, JW; Newhouse, N; Rothberg, PG; Vierhile, A, 2011
)
1.38
"Flupirtine has been found to activate inwardly rectifying potassium conductances and hence to indirectly inhibit the activation of NMDA receptors."( The potassium channel modulator flupirtine shifts the frequency-response function of hippocampal synapses to favour LTD in mice.
Azad, SC; Dodt, HU; Eder, M; Hapfelmeier, G; Rammes, G; Simon, W; Zieglgänsberger, W, 2004
)
1.33
"Flupirtine has been shown to function as a neuroprotectant and is presently used in man to treat a number of conditions. "( Flupirtine attenuates sodium nitroprusside-induced damage to retinal photoreceptors, in situ.
Fawcett, RJ; Osborne, NN, 2007
)
3.23
"Flupirtine, which has been in clinical use since 10 years ago, prevents the toxic effect of PrP, the presumed etiologic agent of the Creutzfeldt-Jakob disease as well as the excitatory amino acid glutamate on cortical neurons."( Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases.
Böhm, M; Meesters, E; Meinhardt, A; Müller, WE; Pergande, G; Perovic, S, 1998
)
1.26
"9. Flupirtine has no pharmacologically relevant affinity for alpha 1-, alpha 2-adrenoceptors, 5-HT1- and 5-HT2-receptors as shown in direct binding studies."( Mode of antinociceptive action of flupirtine in the rat.
Borbe, HO; Brune, K; Nickel, B; Szelenyi, I, 1989
)
1.07
"Flupirtine has a different structure from existing analgesics. "( Flupirtine--a new centrally acting analgesic with unique chemical structure.
Engel, J, 1987
)
3.16
"Flupirtine has no local anesthetic activity in mice but some weak effects on the cornea of rabbits."( [General pharmacologic studies on the analgesic flupirtine].
Achterrath-Tuckermann, U; Jakovlev, V; Stroman, F; Thiemer, K; von Schlichtegroll, A, 1985
)
1.25

Actions

Flupirtine may lower the activity of NMDA receptors, thus causing ATP levels to be less affected in the presence of the drug as a secondary effect. It is the first representative of a pharmacological class denoted the 'selective neuronal potassium channel openers'

ExcerptReferenceRelevance
"Flupirtine displays indirect NDMA receptor antagonism via activation of potassium channels and is the first representative of a pharmacological class denoted the 'selective neuronal potassium channel openers'."( Flupirtine in pain management: pharmacological properties and clinical use.
Devulder, J, 2010
)
2.52
"Flupirtine may lower the activity of NMDA receptors, thus causing ATP levels to be less affected in the presence of the drug as a secondary effect."( Protection of rabbit retina from ischemic injury by flupirtine.
Osborne, NN; Pergande, G; Schwarz, M, 1996
)
1.27
"Flupirtine displays a bimodal activity."( Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases.
Böhm, M; Meesters, E; Meinhardt, A; Müller, WE; Pergande, G; Perovic, S, 1998
)
1.26
"Flupirtine does not produce opiate type physical dependence."( Comparative physical dependence studies in rats with flupirtine and opiate receptor stimulating analgesics.
Aledter, A; Nickel, B, 1987
)
1.24
"Flupirtine was found to inhibit dose-dependently the collagen - but not the primary adenosine diphosphate-induced aggregation of human platelets, being again 1 order of magnitude less potent than indometacin (IC50: 4.0 vs."( The action of flupirtine on prostaglandin formation and platelet aggregation in vitro.
Darius, H; Schrör, K, 1985
)
1.35

Treatment

The flupirtine treatment regimen used in the current study significantly reduced brain injury at acute time point in an animal model of neonatal hypoxic-ischemic encephalopathy. Pre-treatment with fl upirtine reduced the increase in escape latency and in swim distance induced by 4VO.

ExcerptReferenceRelevance
"Flupirtine treatment significantly reduced HI-induced hippocampal and cortical tissue loss at acute time point. "( Effects of a potassium channel opener on brain injury and neurologic outcomes in an animal model of neonatal hypoxic-ischemic injury.
Busquet, N; Diaz, MJ; Gonzalez, MI; Lam, PM; Laoprasert, M; Raol, YH; Sampath, D; White, AM, 2020
)
2
"The flupirtine treatment regimen used in the current study significantly reduced brain injury at acute time point in an animal model of neonatal hypoxic-ischemic encephalopathy. "( Effects of a potassium channel opener on brain injury and neurologic outcomes in an animal model of neonatal hypoxic-ischemic injury.
Busquet, N; Diaz, MJ; Gonzalez, MI; Lam, PM; Laoprasert, M; Raol, YH; Sampath, D; White, AM, 2020
)
1.12
"The flupirtine-treated group showed less impairment in learning and memory and less obvious pathological changes in the brain following RFS compared with the phenobarbital-treated group."( Protective effect of the KCNQ activator flupirtine on a model of repetitive febrile seizures.
He, X; Liu, W; Liu, Y; Peng, B; Wang, H; Wang, Y; Yin, J; Yu, F, 2011
)
1.12
"Pretreatment with flupirtine significantly reduced the infarct area (controls: 24.3 +/- 4.8 mm2, 1 mg/kg flupirtine: 20.1 +/- 3.6 mm2 and 10 mg/kg flupirtine: 19.5 +/- 3.9 mm2; P < 0.05), whereas postischemic application of flupirtine failed to reduce the infarct area."( Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration.
Cao, W; Krieglstein, J; Rupalla, K, 1995
)
2.06
"Pre-treatment with flupirtine reduced the increase in escape latency and in swim distance induced by 4VO."( Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats.
Block, F; Pergande, G; Schwarz, M, 1997
)
2.06

Toxicity

ExcerptReferenceRelevance
" A similar number of adverse reactions occurred in each group but patients receiving pentazocine seemed to be more likely to develop reactions affecting the central nervous system, an important point in the therapy of ill, but often ambulant patients."( Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain.
Scheef, W, 1987
)
0.54
" The results were subjected to statistical analysis with a two-factor partlyhierarchical anova and no toxic effects were detected."( [An ocular toxicity study with flupirtine as an example of evaluation of possible ocular drug side effects in human volunteers (author's transl)].
Koch, HR; Kremer, F; Marzinkowski, A; Trier, HG, 1982
)
0.55
" Doses in a range up to maximum no side effect doses were tested for antihyperalgesic effects in rats with hyperalgesia."( CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
Cooke, I; Goodchild, CS; Kolosov, A, 2010
)
0.36
"The maximum no side effect dose of leconotide (2 mg/kg intravenously) caused 51."( CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
Cooke, I; Goodchild, CS; Kolosov, A, 2010
)
0.36
" Patients were informed to report any adverse effect encountered during the study period."( Efficacy and safety of flupirtine maleate and tramadol hydrochloride in postoperative pain management--a prospective randomised double blinded study.
Biswas, A; Das, AK; Kamal, F; Naser, SM; Prakash, R; Rahaman, QM; Sarkar, N, 2012
)
0.69

Pharmacokinetics

ExcerptReferenceRelevance
" Mean elimination half-life of flupirtine was higher in elderly patients than in younger normal subjects, and this was associated with an increased maximum serum concentration and reduced clearance."( Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment.
Abrams, SM; Ankier, SI; Baker, LR; Crome, P; Johnston, A; Niebch, G; Turner, P; Warrington, SJ; White, AS, 1988
)
0.88
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The aim of this study was to evaluate the pharmacokinetic profiles of FLU after IV and PO administration in healthy cats."( Pharmacokinetic profiles of the analgesic drug flupirtine in cats.
De Vito, V; Giorgi, M; Kowalski, CJ; Lebkowska-Wieruszewska, B; Owen, H, 2014
)
0.66
" The aim of this study was to evaluate the pharmacokinetic profiles of FLU after intravenous (IV), oral immediate release (POIR), oral prolonged release (POPR) and rectal (RC) administrations in healthy dogs."( Pharmacokinetic profiles of the analgesic flupirtine in dogs after the administration of four pharmaceutical formulations.
De Vito, V; Giorgi, M; Kowaski, CJ; Lisowski, A; Shaban, A; Łebkowska-Wieruszewska, B, 2015
)
0.68
" The pharmacokinetic profiles after extravascular administrations showed similar trends."( Pharmacokinetic profiles of the analgesic flupirtine in dogs after the administration of four pharmaceutical formulations.
De Vito, V; Giorgi, M; Kowaski, CJ; Lisowski, A; Shaban, A; Łebkowska-Wieruszewska, B, 2015
)
0.68
"This study provides pharmacokinetic data that can be used to design further studies to investigate FLU in dogs."( Pharmacokinetic profiles of the analgesic flupirtine in dogs after the administration of four pharmaceutical formulations.
De Vito, V; Giorgi, M; Kowaski, CJ; Lisowski, A; Shaban, A; Łebkowska-Wieruszewska, B, 2015
)
0.68
" Neither age nor renal function was a predominant factor of pharmacokinetic variability."( Effects of advanced age and renal dysfunction on the single- and repeated-dose pharmacokinetics of modified-release flupirtine.
de Mey, C; Deliyska, B; Gatchev, E; Terhaag, B, 2015
)
0.63
" The aim of this study was to evaluate the pharmacokinetic profiles of FLU after IV and PO administration in healthy horses."( Pharmacokinetics and disposition of flupirtine in the horse.
De Vito, V; Giorgi, M; Owen, H; Poapolathep, A; Rychshanova, R; Sgorbini, M, 2016
)
0.71

Bioavailability

ExcerptReferenceRelevance
" The bioavailability from the capsule amounted to 90%, from the suppository to 72."( [Pharmacokinetics and biotransformation of the analgesic flupirtine in humans].
Hlavica, P; Niebch, G, 1985
)
0.51
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" The oral bioavailability was approximately 40%."( Pharmacokinetic profiles of the analgesic drug flupirtine in cats.
De Vito, V; Giorgi, M; Kowalski, CJ; Lebkowska-Wieruszewska, B; Owen, H, 2014
)
0.66
" Repeated administration of flupirtine MR showed lower bioavailability (∼ 60%)."( Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.
Bednarski, PJ; Borlak, J; Keiser, M; Methling, K; Modess, C; Nassif, A; Rosskopf, D; Scheuch, E; Siegmund, W; Terhaag, B, 2015
)
0.97
" The bioavailability values after POIR, POPR and RC were 41."( Pharmacokinetic profiles of the analgesic flupirtine in dogs after the administration of four pharmaceutical formulations.
De Vito, V; Giorgi, M; Kowaski, CJ; Lisowski, A; Shaban, A; Łebkowska-Wieruszewska, B, 2015
)
0.68
" The oral bioavailability was 71."( Pharmacokinetics and disposition of flupirtine in the horse.
De Vito, V; Giorgi, M; Owen, H; Poapolathep, A; Rychshanova, R; Sgorbini, M, 2016
)
0.71
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Plasma concentrations of flupirtine measured 2 h after dosing linearly increased as a function of the administered dose. On the basis of this pooled analysis of individual data from 8 controlled clinical trials involving patients suffering from sub-acute/chronic musculoskeletal pain, the efficacy of fl upirtine was superior to placebo across its effective and approved dosage range.

ExcerptRelevanceReference
" Plasma concentrations of flupirtine measured 2 h after dosing linearly increased as a function of the administered dose."( Dose-related analgesic effects of flupirtine.
Borbe, HO; Friedmann, T; Hummel, T; Kobal, G; Niebch, G; Pauli, E, 1991
)
0.86
" The treatment groups revealed no differences in baseline pain and the dosage was similar in each."( Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain.
Scheef, W, 1987
)
0.54
" The average daily dosage was 300 mg."( On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis.
Aigner, M; Herrmann, WM; Kern, U, 1987
)
0.51
" dosage schedule produces average steady-state blood levels equivalent to the peak response for a single 200 mg dose."( Clinical experience with flupirtine in the U.S.
Arndt, WF; McMahon, FG; Montgomery, PA; Newton, JJ; Perhach, JL, 1987
)
0.58
" No tolerance developed to the analgesic activity of flupirtine maleate in mice or rats dosed for up to 19 consecutive days."( Abuse potential and physical dependence liability studies with flupirtine maleate in laboratory animals.
Diamantis, W; Gordon, R; Sofia, RD, 1987
)
0.76
" Moreover, also the dosage (number of capsules/day) was similar in both groups."( [Flupirtine in patients with cancer pain].
Scheef, W; Wolf-Gruber, D, 1985
)
1.18
" The comparison drug pentazocine and placebo were administered in the same dosage regimen (a single dose of pentazocine amounting to 50 mg)."( [The effect of the analgesic flupirtine on automobile driving].
Biehl, B, 1985
)
0.56
" All patients were treated with a 2 x 100 mg daily dosage of oral flupirtine for 3 weeks in an open prospective design."( The use of flupirtine in treatment of tinnitus.
De Ridder, D; Salembier, L; Van de Heyning, PH, 2006
)
0.96
" Monotherapy with katadolon was administered in dosage 100 mg 3 times a day during 1 month."( [Use of katadolon in the treatment of abuse headache].
Filatova, EG; Naprienko, MV, 2006
)
0.33
" Dose-response relationships were determined for nonsedating doses of both drugs given alone and together in combination in causing antinociception in two nociception paradigms: carrageenan paw inflammation and streptozotocin-induced diabetic neuropathy."( Combination therapy with flupirtine and opioid: studies in rat pain models.
Cooke, I; Goodchild, CS; Kolosov, A; Tucker, AP, 2008
)
0.65
"On the basis of this pooled analysis of individual data from 8 controlled clinical trials involving patients suffering from sub-acute/chronic musculoskeletal pain, the efficacy of flupirtine was superior to placebo across its effective and approved dosage range."( Efficacy and tolerability of flupirtine in subacute/ chronic musculoskeletal pain - results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials.
Mueller-Schwefe, GH; Terhaag, B; Ueberall, MA, 2011
)
0.85
" Dose-response curves for morphine (0."( Flupirtine enhances the anti-hyperalgesic effects of morphine in a rat model of prostate bone metastasis.
Cooke, I; Goodchild, CS; Kolosov, A; Williams, ED, 2012
)
1.82
" Mean daily FLP dosage was 805 mg (range 200-3,000 mg)."( Abuse liability of flupirtine revisited: implications of spontaneous reports of adverse drug reactions.
Connemann, BJ; Freudenmann, RW; Gahr, M; Hiemke, C; Schönfeldt-Lecuona, C, 2013
)
0.72
" Moreover, oral dosing with flupirtine (30 mg/kg/day) prevented short-term in vivo hypoxia from increasing pulmonary vascular resistance and sensitizing the arteries to acute hypoxia."( Role of Kv7 channels in responses of the pulmonary circulation to hypoxia.
Brennan, S; Ghaly, Y; Gurney, AM; Herget, J; Joshi, S; Mizera, R; Novotna, J; Sedivy, V; Zaloudikova, M, 2015
)
0.71
" Thus, the methods were suitable to quantify flupirtine absorption and metabolic disposition in man after single intravenous and oral dosing (100mg) and repeated oral administration (400mg once daily)."( Quantitative LC-MS/MS determination of flupirtine, its N-acetylated and two mercapturic acid derivatives in man.
Bednarski, PJ; Methling, K; Oswald, S; Scheuch, E; Siegmund, W, 2015
)
0.95
" Further, daily dosing of flupirtine decreased the seizure burden over 3 days following HI-induction, and modified the natural evolution of acute seizures."( Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy.
Raol, YH; Sampath, D; Valdez, R; White, AM, 2017
)
1.06
"Drug combinations are commonly used in pain management, which can produce potent analgesic effects with reduced dosage and adverse effects."( Flupirtine and antihistamines exert synergistic anti-nociceptive effects in mice.
Bao, Y; Chen, Y; Huang, C; Qin, H; Xiao, X; Zhang, G; Zhou, H; Zhu, J; Zhuang, T, 2023
)
2.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminopyridineCompounds containing a pyridine skeleton substituted by one or more amine groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (97)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency28.37090.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency28.37090.025120.237639.8107AID886; AID893
thioredoxin reductaseRattus norvegicus (Norway rat)Potency31.44860.100020.879379.4328AID488773; AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency25.11890.012610.691788.5700AID887
USP1 protein, partialHomo sapiens (human)Potency15.00300.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency0.02820.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624146
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency3.98110.00137.762544.6684AID914; AID915
regulator of G-protein signaling 4Homo sapiens (human)Potency8.42880.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency22.84650.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
arylsulfatase AHomo sapiens (human)Potency26.85451.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.19170.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
hexokinase-4 isoform 1Homo sapiens (human)Potency0.89132.511913.800328.1838AID743205
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency25.11890.00636.904339.8107AID883
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency37.93300.134610.395030.1313AID1347049
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency6.30960.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID488953
glucokinase regulatory proteinHomo sapiens (human)Potency0.89132.511913.800328.1838AID743205
mitogen-activated protein kinase 1Homo sapiens (human)Potency15.84890.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency14.92090.133725.412989.1251AID588795
eyes absent homolog 2 isoform aHomo sapiens (human)Potency50.11871.199814.641950.1187AID488837
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency26.85450.425612.059128.1838AID504536
tumor susceptibility gene 101 proteinHomo sapiens (human)Potency44.66840.129810.833132.6090AID485342
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency10.00000.050127.073689.1251AID588590
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.94330.031610.279239.8107AID884; AID885
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency19.95260.058010.694926.6086AID602310
caspase-1 isoform alpha precursorHomo sapiens (human)Potency12.58930.000311.448431.6228AID900
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.58930.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency20.10710.00638.235039.8107AID881; AID883
Caspase-7Homo sapiens (human)Potency10.00003.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Single-stranded DNA cytosine deaminaseHomo sapiens (human)Potency28.183828.183860.145389.1251AID1347427
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency37.93300.07578.474229.0628AID504547
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency22.38720.004023.8416100.0000AID485290
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID2323
acetylcholinesteraseHomo sapiens (human)Potency34.67130.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.30170.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency25.16330.141337.9142100.0000AID1490; AID2701
USP1 protein, partialHomo sapiens (human)Potency79.43280.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency26.80470.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency24.70280.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency25.15670.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.73770.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency56.23410.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency30.94430.001530.607315,848.9004AID1224819; AID1224820; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency15.84890.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.34910.000229.305416,493.5996AID743079
GVesicular stomatitis virusPotency15.48710.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency3.09010.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency27.33420.00018.4406100.0000AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency31.82900.035520.977089.1251AID504332; AID588346
aryl hydrocarbon receptorHomo sapiens (human)Potency20.86630.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency33.49150.001723.839378.1014AID743083
Bloom syndrome protein isoform 1Homo sapiens (human)Potency28.18380.540617.639296.1227AID2364; AID2528
galactokinaseHomo sapiens (human)Potency31.62280.943115.289453.0367AID493189
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency3.54810.354828.065989.1251AID504847
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency11.88320.000323.4451159.6830AID743065
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency35.48130.010323.856763.0957AID2662
DNA polymerase eta isoform 1Homo sapiens (human)Potency28.18380.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency2.78300.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID463097
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.42390.005612.367736.1254AID624032
M-phase phosphoprotein 8Homo sapiens (human)Potency39.81070.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency14.12540.00419.962528.1838AID2675
Interferon betaHomo sapiens (human)Potency15.48710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency27.18170.002319.595674.0614AID651631
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)35.50000.11007.190310.0000AID1443980; AID1473738
Serine hydroxymethyltransferase, mitochondrialHomo sapiens (human)IC50 (µMol)0.93330.43653.58839.7700AID1619186
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)EC50 (µMol)0.56000.04001.52084.3800AID1557153
Potassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)EC50 (µMol)0.56000.04001.32274.3800AID1557153
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)EC2 (µMol)1.79000.33001.06252.0000AID1634031; AID1634032
Potassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)EC2 (µMol)2.00000.33001.16502.0000AID1634031
Potassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)EC2 (µMol)4.56003.50004.56005.6200AID1634033; AID1634034
Potassium voltage-gated channel subfamily KQT member 5Homo sapiens (human)EC2 (µMol)2.54000.34001.80673.5000AID1634032; AID1634034
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (294)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
protein targetingPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
protein import into nucleusPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
exocytosisPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
endocytosisPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
chemical synaptic transmissionPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
gene expressionPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
response to auditory stimulusPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
response to organic cyclic compoundPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
neuron remodelingPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
neuronal action potentialPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
nerve developmentPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
psychomotor behaviorPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
regulation of synaptic plasticityPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
neuron apoptotic processPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
mitochondrial depolarizationPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
membrane hyperpolarizationPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
cellular response to calcium ionPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
apoptosome assemblyPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
excitatory chemical synaptic transmissionPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
inhibitory chemical synaptic transmissionPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
action potential initiationPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
regulation of action potential firing thresholdPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
substantia propria of cornea developmentPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
chemical synaptic transmissionPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
nervous system developmentPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
regulation of oxidative phosphorylationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-serine metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-serine biosynthetic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
one-carbon metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
positive regulation of cell population proliferationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
response to type I interferonSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
tetrahydrofolate interconversionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
tetrahydrofolate metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein tetramerizationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein homotetramerizationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
regulation of mitochondrial translationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein K63-linked deubiquitinationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
regulation of aerobic respirationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine biosynthetic process from serineSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
inner ear morphogenesisPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
mRNA processingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic diversification of immunoglobulinsSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic hypermutation of immunoglobulin genesSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
B cell differentiationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
regulation of nuclear cell cycle DNA replicationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to bacteriumSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
isotype switchingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cellular response to lipopolysaccharideSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA cytosine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine to uridine editingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
negative regulation of single stranded viral RNA replication via double stranded DNA intermediateSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to virusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 5Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (95)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
ankyrin bindingPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
chromatin bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine hydroxymethyltransferase activitySerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-allo-threonine aldolase activitySerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
amino acid bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
pyridoxal phosphate bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
identical protein bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
potassium channel activityPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytidine deaminase activitySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
zinc ion bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
ubiquitin protein ligase bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
identical protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
RNA bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 5Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 5Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
mitochondrionPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
node of RanvierPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
axon initial segmentPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
synapsePotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 3Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
node of RanvierPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
axon initial segmentPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
synapsePotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
cytoplasmSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial inner membraneSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial matrixSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
microtubule cytoskeletonSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial nucleoidSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
extracellular exosomeSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
BRISC complexSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
cytoplasmSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
basal plasma membranePotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytosolSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein-containing complexSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
P-bodySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 5Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 5Homo sapiens (human)
clathrin coatPotassium voltage-gated channel subfamily KQT member 5Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (173)

Assay IDTitleYearJournalArticle
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1291851Neuroprotective activity against etoposide-induced apoptosis in rat PC12 cells assessed as cell viability at 3 uM preincubated for 4 hrs followed by etoposide addition measured after 48 hrs by prestoblue staining based fluorescence assay (Rvb = 52 %)2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1557154Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay relative to retigabine2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1861508Agonist activity at Kv7.2 (unknown origin) assessed as shifting of voltage dependent activation to more negative potentials at 5 uM by SyncroPatch assay2022Bioorganic & medicinal chemistry letters, 09-01, Volume: 71Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1477018Neuroprotective activity against etoposide-induced apoptosis in human IMR90-c4 cells assessed as cell viability at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 36 hrs by PrestoBlue assay relative to control2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID311933Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1604622Activation of human Kv7.2 expressed in CHO cells assessed as increase in current amplitude at 10 uM measured at holding potential of 0 mV by whole cell patch clamp electrophysiology assay relative to control
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1861509Agonist activity at Kv7.2 W236L mutant (unknown origin) assessed as shifting of voltage dependent activation to more negative potentials at 5 uM by SyncroPatch assay2022Bioorganic & medicinal chemistry letters, 09-01, Volume: 71Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.
AID1634031Agonist activity at human Kv7.2/Kv7.3 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1477039Neuroprotective activity against etoposide-induced apoptosis in human SH-SY5Y cells assessed as cell viability at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 12 to 48 hrs by PrestoBlue assay relative to control2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1634034Agonist activity at human Kv7.4/Kv7.5 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1477025Neuroprotective activity against etoposide-induced apoptosis in rat PC12 cells assessed as increase in Bcl2/Bax ratio at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 24 hrs by Western blot method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1477030Induction of autophagy in rat PC12 cells at 10 uM after 48 hrs by MDC staining-based flow cytometric method relative to control2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1291852Neuroprotective activity against serum starvation-induced apoptosis in rat PC12 cells assessed as cell survival at 1 to 30 uM after 24 hrs by prestoblue staining based fluorescence assay (Rvb = 55%)2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity.
AID1477024Antagonist activity at NMDA receptor in human IMR90-c4 cells assessed as decrease in NMDA-mediated reduction in cell viability at 0.1 to 10 uM by PrestoBlue assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1477020Neuroprotective activity in rat PC12 cells assessed as decrease in H2O2-induced reactive oxygen species generation at 10 uM by CellROX/DAPI-blue staining-based fluorescence microscopic method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1477015Neuroprotective activity against etoposide-induced apoptosis in human IMR90-c4 cells assessed as increase in cell viability at 3 to 30 uM pretreated for 4 hrs followed by etoposide challenge measured after 36 hrs by PrestoBlue assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1477012Neuroprotective activity against etoposide-induced apoptosis in rat PC12 cells assessed as cell viability at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 48 hrs by PrestoBlue assay (Rvb = 52.13 +/- 1.13%)2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1477021Neuroprotective activity against H2O2-induced apoptosis in rat PC12 cells assessed as increase in cell viability at 1 to 30 uM after 4 hrs by PrestoBlue assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1557153Agonist activity at human KCNQ2/3 expressed in HEK293 cells by FLIPR based thallium influx assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.
AID1604623Activation of human Kv7.2 expressed in CHO cells assessed as increase in current amplitude at 10 uM measured at holding potential of -40 mV by whole cell patch clamp electrophysiology assay relative to control
AID1477034Induction of autophagy in rat PC12 cells assessed as increase in beclin 1 expression at 3 uM after 24 hrs by Western blot method relative to control2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1473947Drug concentration at steady state in human at 100 to 600 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1477031Induction of autophagy in rat PC12 cells at 3 uM after 48 hrs by MDC staining-based flow cytometric method relative to control2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1634032Agonist activity at human Kv7.3/Kv7.5 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID1473946AUC in human at 100 to 600 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1634035Selectivity index, ratio of EC2x for human Kv7.4/5 expressed in HEK293 cells to EC2x for EC2x for human Kv7.2/3 expressed in HEK293 cells
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1634033Agonist activity at human Kv7.4 expressed in HEK293 cells assessed as drug concentration that doubles the conductance at voltage leading to 15% channel activation at holding potential of at -80 mV by whole cell patch clamp electrophysiology assay
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1477023Antagonist activity at NMDA receptor in human IMR90-c4 cells assessed as decrease in NMDA-mediated reduction in cell viability at 30 uM by PrestoBlue assay2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1477028Neuroprotective activity against etoposide-induced apoptosis in rat PC12 cells assessed as increase in Bcl2/Bax ratio at 3 uM pretreated for 4 hrs followed by etoposide challenge measured after 48 hrs by Western blot method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473948Ratio of drug concentration at steady state in human at 100 to 600 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346696Human Kv7.2 (Voltage-gated potassium channels)2004The Journal of neuroscience : the official journal of the Society for Neuroscience, Jan-21, Volume: 24, Issue:3
M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (293)

TimeframeStudies, This Drug (%)All Drugs %
pre-199046 (15.70)18.7374
1990's45 (15.36)18.2507
2000's63 (21.50)29.6817
2010's116 (39.59)24.3611
2020's23 (7.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.54 (24.57)
Research Supply Index5.83 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index123.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials48 (16.44%)5.53%
Trials0 (0.00%)5.53%
Reviews24 (8.22%)6.00%
Reviews0 (0.00%)6.00%
Case Studies16 (5.48%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other204 (69.86%)84.16%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-β1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis [NCT00623415]Phase 230 participants (Actual)Interventional2007-12-31Terminated
Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine After Intravenous, Single Dose and Chronic Oral Administration in Healthy Subjects Genotyped for NAT2, UGT1A1 and GSTP1 [NCT01676246]Phase 136 participants (Actual)Interventional2008-05-31Completed
Evaluation of the Effect of the K+-Channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo: a Randomised Controlled Trial [NCT01450865]Phase 120 participants (Actual)Interventional2009-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]